Nintedanib in Patients With Advanced Esophagogastric Cancer

NCT02234596 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Esophagogastric Adenocarcinoma

Interventions

DRUG: Nintedanib

Sponsor

Memorial Sloan Kettering Cancer Center